National Institute for Health and Care Excellence

# Epilepsies in children, young people and adults (update)

**Consultation on draft quality standard – deadline for comments 5pm on 13/07/23**

**Please email your completed form to**:QualityStandards@nice.org.uk

Note: During development of the draft quality standard, the Medicines and Healthcare products Regulatory Agency announced that new safety measures for valproate-containing medicines are to be put in place. NICE’s guideline on epilepsies in children, young people and adults will be updated when more information on these safety measures is published. The draft quality standard does not cover the new safety measures.

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.

Use the form to comment on the content of the quality standard (i.e. the statements and other sections e.g. rationale, measures etc.), as well as answer the following questions:

* 1. Does this draft quality standard accurately reflect the key areas for quality improvement?
	2. Can data for the proposed quality measures be collected locally? Please include in your answer any data sources that can be used or reasons why data cannot be collected.
	3. Do you think each of the statements in this draft quality standard would be achievable by local services given the net resources needed to deliver them? Please describe any resource requirements that you think would be necessary for any statement. Please describe any potential cost savings or opportunities for disinvestment.
	4. For draft quality statement 1: Is it feasible for epilepsy specialist nurses to be the ‘clinician with expertise in epilepsy’ who identifies the cause of a seizure and ensures a correct diagnosis is made?
	5. For draft quality statement 5: Statement 5 covers planned epilepsy appointments. Are there specific types of epilepsy appointments that should be included or excluded from this statement?
	6. For draft quality statement 5: Is there enough time and capacity at epilepsy appointments to ask about cognitive function, mental health, social and emotional wellbeing and, where relevant, neurodevelopment and learning disabilities?
	7. For draft quality statement 5: Statement 5 covers cognitive function, mental health, social and emotional wellbeing, and, where relevant, neurodevelopment and learning disabilities. It also covers all people with epilepsy. Would it be helpful to focus the statement on a smaller number of areas or a particular population group? If so, what should it focus on?
	8. For draft quality statement 5: What is an appropriate outcome measure for this statement? Please include any known data sources for suggestions.
	9. What are the challenges to implementing the NICE guidance underpinning this quality standard? Please say why and for whom. Please include any suggestions that could help users overcome these challenges (for example, existing practical resources or national initiatives).

# Organisation details

|  |  |
| --- | --- |
| **Organisation name**(if you are responding as an individual rather than a registered stakeholder please leave blank) |  |
| **Disclosure**Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry. |  |
| **Name of person completing form** |  |
| **Supporting the quality standard**Would your organisation like to express an interest in formally supporting this quality standard? [More information.](https://www.nice.org.uk/standards-and-indicators/get-involved/support-a-quality-standard) |  |
| **Type** | **[Office use only]** |

# Comments on the draft quality standard

|  |  |  |
| --- | --- | --- |
| **Comment number** | Statement or question numberOr ‘general’ for comments on the whole document | CommentsInsert each comment in a new row.Do not paste other tables into this table because your comments could get lost – type directly into this table. |
| *Example 1* | *Statement 1* | *This statement could be improved by…* |
| 1 | General |  |
| 2 | Question 1 |  |
| 3 | Question 2 |  |
| 4 | Question 3 |  |
| 5 | Question 4 |  |
| 6 | Question 5 |  |
| 7 | Question 6 |  |
| 8 | Question 7 |  |
| 9 | Question 8 |  |
| 10 | Question 9 |  |
| 11 | Statement 1 |  |
| 12 | Statement 2 |  |
| 13 | Statement 3 |  |
| 14 | Statement 4 |  |
| 15 | Statement 5 |  |
|  |  |  |

# Insert more rows as needed

# Checklist for submitting comments

* Use this form and submit it as a Word document (not a PDF).
* Complete the disclosure about links with, or funding from, the tobacco industry.
* Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
* Do not paste other tables into this table – type directly into the table.
* **Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.**
* Do not include medical information about yourself or another person from which you or the person could be identified.
* Spell out any abbreviations you use

Please return to QualityStandards@nice.org.uk

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

Comments received from registered stakeholders and respondents during our stakeholder engagements are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.